Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Zafirlukast or its saltsPDL I DEC / 13
Zalcitabine or its saltsPDL I DEC / 13
Zaleplon or its salts or its derivativesPDL I NOV / 18
Zanamivir or its salts or derivativesPDL I DEC / 13
ZeranolC3 I SEP / 98
ZidovudinePDL I DEC / 13
Zinc chloride in injectable form for parenteral nutrition I JAN / 03
Zinc sulfate in injectable form for parenteral nutrition I JAN / 03
Ziprasidone or its saltsPDL I DEC / 13
Zoledronic acid or its salts or derivativesPDL I DEC / 13
Zolmitriptan or its saltsPDL I DEC / 13
Zolpidem and any salts thereofTS I JAN / 03
Zomepirac or its saltsPDL I DEC / 13
Zopiclone or its saltsPDL I DEC / 13
ZucapsaicinPDL I DEC / 13
Zuclopenthixol or its salts or derivativesPDL

Including but not limited to zuclopenthixol decanoate, zuclopenthixol hydrochloride.

I DEC / 13

16 résultats

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled